Table 4.
Alternative splicing of CD38 and relative abundance of protein coding transcripts.
| Population | n | CD38-001 | % CD38-001 | CD38-001 only | % CD38-001 only | Number of annotated reads other than CD38-001 |
||
|---|---|---|---|---|---|---|---|---|
| >1% | >5% | >10% | ||||||
| MBC | 4 | 1 | 25.0 | 1 | 25.0 | 0 | 0 | 0 |
| PPC | 4 | 4 | 100 | 2 | 50.0 | 0 | 0 | 0 |
| BMPC | 10 | 10 | 100 | 3 | 33.3 | 0 | 0 | 0 |
| AL | 124 | 124 | 100 | 96 | 77.4 | 0 | 0 | 0 |
| MGUS | 52 | 52 | 100 | 36 | 69.2 | 3 | 0 | 0 |
| AMM | 29 | 29 | 100 | 17 | 58.6 | 0 | 0 | 0 |
| MM | 388 | 388 | 100 | 247 | 63.7 | 1 | 0 | 0 |
| HMCL | 26 | 22 | 84.6 | 15 | 57.7 | 0 | 0 | 0 |
Shown is the percentage of samples with detection of the full-length eight-exon transcript CD38.001 (protein coding) in comparison to the percentage of samples with detection of any other CD38 transcript (including non-protein coding) above the levels of 1, 5, and 10%, respectively. The highest non-CD38-001 frequency found in any of the samples is 2.1%, the highest frequency of the alternate protein-coding transcript CD38-005 is 1.8%.
MBC, memory B-cells; PPC, polyclonal plasmablastic cells; BMPC, (normal) bone marrow plasma cells; AL, AL-amyloidosis; MGUS, monoclonal gammopathy of unknown significance; (A)MM, (asymptomatic) multiple myeloma; MMR, relapsed/refractory myeloma; HMCL, human myeloma cell line.